PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY

被引：0
|
作者：
Cella, D. [1 ]
Ritchie, E. [2 ]
Fabbiano, F. [3 ]
Pigneux, A. [4 ]
Kanda, Y. [5 ]
Ivanescu, C. [6 ]
Pandya, B. [7 ]
Shah, M., V [8 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Weill Cornell Med, New York, NY USA
[3] Azienda Osped Osped Riuniti Villa Sofia Cervello, Sicily, Italy
[4] Ctr Hosp Univ Bordeaux, Bordeaux, France
[5] Jichi Med Univ, Shimotsuke, Tochigi, Japan
[6] IQVIA, Amsterdam, Netherlands
[7] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[8] Astellas Pharma US Inc, Northbrook, IL USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN485
引用
收藏
页码：S531 / S531
页数：1
相关论文
共 50 条
  • [1] The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3-Mutated (FLT3mut+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study
    Ritchie, Ellen K.
    Cella, David
    Fabbiano, Francesco
    Pigneux, Arnaud
    Kanda, Yoshinobu
    Ivanescu, Cristina
    Pandya, Bhavik J.
    Shah, Manasee V.
    BLOOD, 2019, 134
  • [2] The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study
    Cella, David
    Ritchie, Ellen K.
    Fabbiano, Francesco
    Pigneux, Arnaud
    Kanda, Yoshinobu
    Ivanescu, Cristina
    Pandya, Bhavik J.
    Shah, Manasee V.
    BLOOD, 2019, 134
  • [3] Relationship between patient-reported outcomes and clinical outcomes in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the ADMIRAL study
    Cella, D.
    Ritchie, E.
    Fabbiano, F.
    Pigneux, A.
    Kanda, Y.
    Ivanescu, C.
    Pandya, B. J.
    Shah, M. V.
    SWISS MEDICAL WEEKLY, 2020, : 15S - 15S
  • [4] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial
    Perl, Alexander E.
    Martinelli, Giovanni
    Cortes, Jorge E.
    Neubauer, Andreas
    Berman, Ellin
    Paolini, Stefania
    Montesinos, Pau
    Baer, Maria R.
    Larson, Richard A.
    Ustun, Celalettin
    Fabbiano, Francesco
    Di Stasi, Antonio
    Stuart, Robert
    Olin, Rebecca
    Kasner, Margaret
    Ciceri, Fabio
    Chou, Wen-Chien
    Podoltsev, Nikolai
    Recher, Christian
    Yokoyama, Hisayuki
    Hosono, Naoko
    Yoon, Sung-Soo
    Lee, Je-Hwan
    Pardee, Timothy
    Fathi, Amir T.
    Liu, Chaofeng
    Liu, Xuan
    Bahceci, Erkut
    Levis, Mark J.
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML
    Ritchie, Ellen K.
    Cella, David
    Fabbiano, Francesco
    Pigneux, Arnaud
    Kanda, Yoshinobu
    Ivanescu, Cristina
    Pandya, Bhavik J.
    Shah, Manasee V. V.
    LEUKEMIA & LYMPHOMA, 2023, 64 (05) : 938 - 950
  • [6] Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML)
    Zeidan, Amer M.
    Qi, Cynthia Z.
    Pandya, Bhavik J.
    Garnham, Andy
    Yang, Hongbo
    Shah, Manasee V.
    BLOOD, 2019, 134
  • [7] Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
    Smith, Catherine C.
    Levis, Mark J.
    Perl, Alexander E.
    Hill, Jason E.
    Rosales, Matt
    Bahceci, Erkut
    BLOOD ADVANCES, 2022, 6 (07) : 2144 - 2155
  • [8] PSYCHOMETRIC ANALYSIS OF PATIENT-REPORTED OUTCOME MEASURES IN FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    Cella, D.
    Corredoira, L.
    Ivanescu, C.
    Pandya, B. J.
    Shah, M., V
    VALUE IN HEALTH, 2020, 23 : S83 - S83
  • [9] Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory AML: phase 3 ADMIRAL trial results
    Perl, Alexander E.
    Martinelli, Giovanni
    Cortes, Jorge E.
    Neubauer, Andreas
    Berman, Ellin
    Paolini, Stefania
    Montesinos, Pau
    Baer, Maria R.
    Larson, Richard A.
    Ustun, Celalettin
    Fabbiano, Francesco
    Di Stasi, Antonio
    Stuart, Robert
    Olin, Rebecca
    Kasner, Margaret
    Ciceri, Fabio
    Chou, Wen-Chien
    Podoltsev, Nikolai
    Recher, Christian
    Yokoyama, Hisayuki
    Hosono, Naoko
    Yoon, Sung-Soo
    Lee, Je-Hwan
    Pardee, Timothy
    Fathi, Amir T.
    Liu, Chaofeng
    Liu, Xuan
    Bahceci, Erkut
    Levis, Mark J.
    SWISS MEDICAL WEEKLY, 2019, 149 : 3S - 4S
  • [10] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial
    Perl, A. E.
    Martinelli, G.
    Cortes, J. E.
    Neubauer, A.
    Berman, E.
    Paolini, S.
    Montesinos, P.
    Baer, M. R.
    Larson, R. A.
    Ustun, C.
    Fabbiano, F.
    Di Stasi, A.
    Stuart, R.
    Olin, R.
    Kasner, M.
    Ciceri, F.
    Chou, W. -C.
    Podoltsev, N.
    Recher, C.
    Yokoyama, H.
    Hosono, N.
    Yoon, S. -S.
    Lee, J. -H.
    Pardee, T.
    Fathi, A. T.
    Liu, C.
    Liu, X.
    Bahceci, E.
    Levis, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 295 - 295
12345